Background: The simple and caged xanthones from Clusiaceae showed significant antineoplastic activity. This study aims to identify structural diverse xanthones and search for novel antitumor natural products from this family plants.
Background
Cratoxylum cochinchinense Blume (Clusiaceae) is a deciduous shrub tree growing abundantly in southeast Asian countries [1] . The leaves, stems, barks, roots and latex of C. cochinchinense have been used as traditional Chinese medicine for the treatment of various diseases such as jaundice, edema, cough, itch, fever, diarrhea, hoarseness, diuretic, flu, colic, ulcer and dental problems and so on [2] [3] [4] . In addition, the young leaves have been used as an herbal substitute for tea and the immature fruit as a spice for cooking [5] . The simple and caged xanthones with significant antineoplastic activity have been reported from previous phytochemical investigations [6] [7] [8] [9] [10] [11] [12] . Aiming to identify structural diverse xanthones and search for novel antitumor natural products from the Clusiaceae [13] [14] [15] [16] [17] [18] , we continued our studies on the petroleum ether-soluble and dichloromethanesoluble portions of the stems and leaves of C. cochinchinense which exhibited moderate cytotoxicity against human myeloid leukemia (HL-60), human prostate cancer (PC-3) and human breast carcinoma (MDA-MB-231) cell lines with IC 50 values of 7.59, 21.49, 19 .63 and 7.86, 32.48, 30.40 μg/ml, respectively. A pair of new enantiomers of xanthones, (+)-and (−)-cracochinxanthone A (1a and 1b), as well as thirty known analogues were obtained (Fig. 1 ). In the present paper, the isolation and structure elucidation of new enantiomers of 1a and 1b, as well as the biological evaluation of some selected xanthones are presented.
Materials and methods

Information of experimental design and resources
The Minimum Standards of Reporting Checklist contains details of the experimental design, and statistics, and resources used in this study (Additional file 1).
General experimental procedures
1 H NMR, 13 C NMR, HSQC, and HMBC were recorded on the Bruker-ARX-400 and Bruker-AV-600 NMR with tetramethylsilane (TMS) as internal standard. HRESIMS spectra were measured on a Bruker micrOTOF-Q mass spectrometer. Optical rotations were measured by the JASCO P-2000 polarimeter. UV spectra were recorded on a Shimadzu UV-2201 spectrometer. ECD spectra were measured on the BioLogic MOS 450 AF/CD at room temperature. Multimode Reader were used by a Varioskan Flash. The semipreparative HPLC was a Shimadzu SPD-20A series equipped with an YMC C 18 column (250 × 20 mm, 5 μm, 2 mL/min). Chiral HPLC was a CHIRALPAK IB (250 × 4.6 mm) from Daicel Chiral Technologies Co., Ltd., China. Column chromatography (CC) was conducted on silica gel (100-200 and 200-300 mesh) and preparative and analytical TLC was performed on precoated GF254 plates (Qingdao Haiyang Chemical Co., Ltd., China), octadecyl silane (ODS) (50 µm, YMC Co., Ltd., Kyoto, Japan) and Sephadex LH-20 (GE Healthcare, Uppsala, Sweden). All the organic solvents were purchased from Yuwang and Laibo Chemicals Industries, Ltd., China.
Plant material
Stems and leaves of Cratoxylum cochinchinense were collected in December 2016, at Mengla County, Xishuangbanna Autonomous Prefecture, People's Republic of China, and were identified by Zhi Na (Kunming Institute of Botany, Chinese Academy of Sciences). The voucher specimen (HNMJY-2016) was deposited in the Department of Natural Products Chemistry, Shenyang Pharmaceutical University, Shenyang, China.
Extraction and isolation
The smashed leaves and stems of C. cochinchinense (10 kg) were macerated with 80% aqueous acetone at room temperature (3 × 80 L, 3 days each time). The combined extracts was suspended in water, and successively partitioned to produce petroleum ether (PE), dichloromethane (CH 2 Cl 2 ), ethyl acetate (EtOAc), n-butyl alcohol (n-BuOH) and water (H 2 O) fractions. The CH 2 Cl 2 extract (140 g) was fractionated on a silica gel CC and eluted with a PE/EtOAc gradient (100:0, 100:1, 100:3, 100:5, 100:7, 100:10, 100:20, 100:30, 100:50, 0:100) to give ten fractions (Fr. A-J). Fraction D was purified by ODS CC with a stepwise gradient elution using MeOH/ H 2 O to afford 23 (154.8 mg), 29 (8.2 mg), 22 (5.8 mg), 26 (8.7 mg) and yield two subfractions D3 and D4. Fr. D3 was subsequently refined over Sephadex LH-20 (MeOH), followed by semi-preparative HPLC using 77% MeOH in H 2 O as a mobile phase to get 19 (15.8 mg, t R = 63.5 min) and 1 (3.2 mg, t R = 93.3 min). Then, 1 was separated by chiral HPLC eluting with n-hexane: isopropanol (90:10) to yield 1a (0.92 mg, t R = 15.4 min) and 1b (1.1 mg, t R = 18.4 min). Fr. D4 was also chromatographed on Sephadex LH-20 (MeOH) and semi-preparative HPLC (64% MeOH in H 2 O) to produce 6 (4.5 mg, t R = 38.4 min) and 9 (6.5 mg, t R = 40.3 min). Fr. F was fractionated by ODS CC (MeOH/H 2 O) to give 27 (7.5 mg), 18 (5.3 mg), 20 (7.9 mg) and three major subfractions F2, F5 and F8. Fr. F2 was successively partitioned by a Sephadex LH-20 column (MeOH) to provide the key subfraction F2.2. Fr. F2.2 was further processed via semi-preparative HPLC using 56% aqueous MeOH as the mobile phase to afford 3 (10.2 mg, t R = 28.0 min) and 4 (7.8 mg, t R = 32.2 min). Fr. F5 was recrystallized with methanol to yield 19 (50.1 mg). Fr. F8 was loaded onto semi-preparative HPLC using 82% aqueous MeOH to gain 24 (6.9 mg, t R = 87.5 min), 25 (10.2 mg, t R = 92.5 min) and 21 (15.2 mg, t R = 121.5 min). Fr. H was subjected to ODS CC, which afford 15 (6.9 mg) through further recrystallization and subfractions H3 and H5. Fr. H3 and Fr. H5 were applied to Sephadex LH-20 column and eluted with MeOH to obtain 7 (5.4 mg) and 8 (7.5 mg), respectively. Fr. I was subjected to ODS CC to furnish 13 (5.2 mg), 14 (2.8 mg), and subfraction I4. Fr. I4 followed by Sephadex LH-20 CC to afford 28 (11.6 mg). Fr. J was rechromatographed over silica gel CC, affording 12 (4.6 mg), 11 (3.2 mg) and 10 (13.4 mg).
The PE extract (69 g) was chromatographed on a silica gel CC and eluted stepwise with a PE/EtOAc gradient system (100:1, 100:3, 100:7, 100:15, 100:50, 100:100, 0:100) to afford the major fractions A′-G′. Fr. C′ was subjected to separation over ODS CC to yield 30 (8.8 mg) and subfraction C′8. Fr. C′8 was further purified over a silica gel CC and followed by semi-preparative HPLC with 90% aqueous MeOH as mobile phase under isocratic condition to furnish 31 ( 
Anticancer assay in vitro
The antiproliferative activities of some selected compounds against the HL-60, PC-3, and MDA-MB-231 cancer cell lines were evaluated. 5-Fluorouracil (5-FU) was used as a positive control. Detailed methodology for the cell growth inhibition test has been described in a previous report [19] . The IC 50 values were calculated by SPSS 16.0 software and results were repeated three times that were expressed as mean ± SD.
Results
Cracochinxanthone A (1) was obtained as a yellow needle, and its molecular formula was determined as C 23 and C-10a, H-6 (δ H 7.28) with C-8 (δ C 107.9) and C-10a, and OH-7 (δ 9.95) with C-6, C-7 and C-8 indicated that the free phenolic hydroxy located at C-7 (Fig. 2 ). Based on these results, the structure of 1 was assigned to a new compound, namely cracochinxanthone A. Cracochinxanthone A might be a racemic mixture due to the smooth ECD curve as well as close to zero optical rotation. Subsequent chiral HPLC separation of 1 gave the corresponding enantiomers 1a and 1b possessing the opposite ECD curves. Their experimental ECD spectra matched well with the calculated ones for R and S, respectively, thus, explicitly assigning the absolute configurations of 1a and 1b (Fig. 3) . And the optical rotations of 1a and 1b were + 10.0 (c 0.06 MeOH) and − 11.3 (c 0.07 MeOH), respectively. Therefore, the structures of 1a and 1b were named as (+) and (−)-cracochinxanthone A.
By comparison with those data from the literatures, the known analogues were identified as cochinchinoxanthone (2) [21] , 1,4,7-trihydroxy-8-methoxyxanthone (3) [22] , gentisein (4) [ [20] , cudratricusxanthone E (20) [36] , γ-mangostin (21) [37] , 1,3,7-trihydroxy-2,4-diisoprenylxanthone (22) [38], cochinchinone A (23) [33] , cochinchinone B (24) [33] , pruniflorone Q (25) [39] , 1,3,5-trihydroxy-6′,6′-dimethyl-2H-pyrano(2′,3:6,7)xanthone (26) [30] , pruniflorone N (27) [40] , xanthone V 1 (28) [41] , osajaxanthone (29) [42] , cochinchinone I (30) [43] , 1,7-dihydroxy-4-(3,7dimethylocta-2,6-dienyl)-5′-(1-hydroxy-1-methylethyl)-4′,5′-dihydrofuro[2′,3′:3,2]-xanthone (31) [44] .
Discussions
The antiproliferative activities of some xanthones were evaluated against HL-60, PC-3, and MDA-MB-231 cancer cell lines ( 
Conclusions
A pair of new racemic mixture of xanthones, (+)-cracochinxanthone A (1a) and (−)-cracochinxanthone A (1b), along with 30 known analogues (2-31) were isolated from the stems and leaves of C. cochinchinense. The antiproliferative activities of some selected compounds against human HL-60, PC-3, and MDA-MB-231 cancer cell lines were screened by the trypan blue and MTT methods. The polyprenylated or geranylated xanthones exhibited potent cytotoxicity against three human malignant cell lines, which could be further developed as potential lead compounds in the design for the treatment of cancer.
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Abbreviations HL-60: human myeloid leukemia cell line; PC-3: human prostate cancer cell line; MDA-MB-231: human breast carcinoma cell line; ODS: octadecyl silane; CC: column chromatography; TMS: tetramethylsilane; PE: petroleum ether; CH 2 Cl 2 : dichloromethane; EtOAc: ethyl acetate; n-BuOH: n-butyl alcohol; H 2 O: water; ECD: electronic circular dichroic spectroscopy; HPLC: high performance liquid chromatography; IC 50 : the concentration of drug required to inhibit cell growth by 50% compared with untreated control.
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